Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Dinter

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 24, 2007
Phosphodiesterase type 4 inhibitors: potential in the treatment of multiple sclerosis?H Dinter
The EMBO Journal|March 1, 1987
Superinduction of the human interferon-beta promoterH Dinter, H Hauser
European Journal of Biochemistry|July 1, 1987
Cooperative interaction of multiple DNA elements in the human interferon-beta promoterH Dinter, H Hauser
Pharmaceutisch Weekblad. Scientific Edition|August 21, 1992
Comparative study on protective gloves for handling cytotoxic medicines: a model study with carmustineH Dinter-Heidorn, G Carstens
Journal of Hypertension|January 1, 1994
Prostaglandins and their receptors: II. Receptor structure and signal transductionK H Thierauch, H Dinter, G Stock
Journal of Molecular Medicine (Berlin, Germany)|March 1, 1997
Multiple sclerosis: pathogenesis and modelsH Dinter, G Stock, H D Perez
Journal of Hypertension|December 1, 1993
Prostaglandins and their receptors: I. Pharmacologic receptor description, metabolism and drug useK H Thierauch, H Dinter, G Stock
Journal of Molecular Medicine (Berlin, Germany)|February 1, 1997
Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosisH Dinter, J Onuffer, D Faulds, et al.
Arzneimittel-Forschung|June 1, 1970
[Effect of quinoline derivatives on pathogenic and apathogenic intestinal microorganisms]M Ellenrieder, P Zeiller, H Dinter, et al.
European Journal of Biochemistry|February 15, 1995
Splice variants of the human EP3 receptor for prostaglandin E2A Schmid, K H Thierauch, W D Schleuning, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 24, 2007
Phosphodiesterase type 4 inhibitors: potential in the treatment of multiple sclerosis?H Dinter
The EMBO Journal|March 1, 1987
Superinduction of the human interferon-beta promoterH Dinter, H Hauser
European Journal of Biochemistry|July 1, 1987
Cooperative interaction of multiple DNA elements in the human interferon-beta promoterH Dinter, H Hauser
Pharmaceutisch Weekblad. Scientific Edition|August 21, 1992
Comparative study on protective gloves for handling cytotoxic medicines: a model study with carmustineH Dinter-Heidorn, G Carstens
Journal of Hypertension|January 1, 1994
Prostaglandins and their receptors: II. Receptor structure and signal transductionK H Thierauch, H Dinter, G Stock
Journal of Molecular Medicine (Berlin, Germany)|March 1, 1997
Multiple sclerosis: pathogenesis and modelsH Dinter, G Stock, H D Perez
Journal of Hypertension|December 1, 1993
Prostaglandins and their receptors: I. Pharmacologic receptor description, metabolism and drug useK H Thierauch, H Dinter, G Stock
Journal of Molecular Medicine (Berlin, Germany)|February 1, 1997
Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosisH Dinter, J Onuffer, D Faulds, et al.
Arzneimittel-Forschung|June 1, 1970
[Effect of quinoline derivatives on pathogenic and apathogenic intestinal microorganisms]M Ellenrieder, P Zeiller, H Dinter, et al.
European Journal of Biochemistry|February 15, 1995
Splice variants of the human EP3 receptor for prostaglandin E2A Schmid, K H Thierauch, W D Schleuning, et al.
Pageof 2